Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic acid in dialysis patients with hyperphosphatemia, hyperparathyroidism and hyperlipidemia
IRCT201402212954N4Phase 3Completed
- Sponsor
- Shahroud University of Medical Sciences
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of niacin in hyperphosphatemia, hyperlipidemia, hyperparathyroidism and 1 more, sponsored by Shahroud University of Medical Sciences. Primary endpoints: Change in serum phosphorus, Change in parathyroid hormone (PTH) and 1 more. Started Mar 2014; status: completed.
02
Drugs
niacin
03
Conditions
hyperphosphatemiahyperlipidemiahyperparathyroidismend-stage kidney disease (ESKD)
Beyond the preview
Go deeper on IRCT201402212954N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT201402212954N4.